The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’…
Jardiance
FDA Issues Complete Response Letter for Type 2 Diabetes Drug Empagliflozin
The FDA has issued a complete response letter to Boehringer Ingelheim and Eli Lilly for the New Drug Application (NDA) …
New Data Shows Empagliflozin Improves Blood Glucose Levels in Type 2 Diabetes Patients
Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin …
